Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice

Drug Metabolism and Disposition

Volumn 41, Issue 4, 2013, Pages 727-734

  Kogame, Akifumi ^a   Tagawa, Yoshihiko ^a   Shibata, Sachio ^a   Tojo, Hideaki ^a   Miyamoto, Maki ^a   Tohyama, Kimio ^a   Kondo, Takahiro ^a   Prakash, Shimoga ^b   Shyu, Wen Chyi ^b   Asahi, Satoru ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 ETHYL N [1 (HYDROXYACETYL)PIPERIDIN 4 YL] 1 METHYL 4 OXO 5 (2 OXO 2 PHENYLETHYL) 3 (2,2,2 TRIFLUOROETHOXY) 4,5 DIHYDRO 1H PYRROLO[3,2 C]PYRIDINE 2 CARBOXAMIDE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; MESSENGER RNA; PYRIDINE DERIVATIVE; SONIC HEDGEHOG PROTEIN; TAK 441; TRANSCRIPTION FACTOR GLI1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG STRUCTURE; FEMALE; GENE EXPRESSION; GLI1 GENE; HUMAN; HUMAN TISSUE; IC 50; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; SKIN CELL; STROMA CELL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION; HEDGEHOG PROTEINS; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASMS; ONCOGENE PROTEINS; PYRIDINES; PYRROLES; RNA, MESSENGER; SKIN; TRANS-ACTIVATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ERINACEIDAE; MUS;

EID: 84875871964     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.049650     Document Type: Article

References (23)

1. Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, and Workman P (2005) Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 11:7023-7032.
2. Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, and Trocóniz IF (2008) Semimechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer 44:142-150.
3. Chen X, Horiuchi A, Kikuchi N, Osada R, Yoshida J, Shiozawa T, and Konishi I (2007) Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: it's inhibition leads to growth suppression and apoptosis. Cancer Sci 98:68-76.
4. Chien JY, Friedrich S, Heathman MA, de Alwis DP, and Sinha V (2005) Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J 7:E544-E559.
5. Curran T and Ng JM (2008) Cancer: Hedgehog's other great trick. Nature 455:293-294.
6. Dayneka NL, Garg V, and Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478.
7. Derendorf H, Lesko LJ, Chaikin P, Colburn WA, Lee P, Miller R, Powell R, Rhodes G, Stanski D, and Venitz J (2000) Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol 40:1399-1418.
8. Euhus DM, Hudd C, LaRegina MC, and Johnson FE (1986) Tumor measurement in the nude mouse. J Surg Oncol 31:229-234.
9. Hidalgo M (2004) New target, new drug, old paradigm. J Clin Oncol 22:2270-2272.
10. Ingham PW and McMahon AP (2001) Hedgehog signaling in animal development: paradigms and principles. Genes Dev 15:3059-3087.
11. Kubo M, Nakamura M, Tasaki A, Yamanaka N, Nakashima H, Nomura M, Kuroki S, and Katano M (2004) Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res 64:6071-6074.
12. Ohashi T, Oguro Y, Tanaka T, Shiokawa Z, Tanaka Y, Shibata S, Sato Y, Yamakawa H, Hattori H, and Yamamoto Y, et al. (2012) Discovery of the investigational drug TAK-441, a pyrrolo [3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. Bioorg Med Chem 20:5507-5517.
13. Phillips RL and Sachs AB (2005) Skin biopsies for the measurement of clinical pharmacodynamic biomarkers. Curr Opin Biotechnol 16:687-690.
14. Rittié L, Stoll SW, Kang S, Voorhees JJ, and Fisher GJ (2009) Hedgehog signaling maintains hair follicle stem cell phenotype in young and aged human skin. Aging Cell 8:738-751.
15. Romer J and Curran T (2005) Targeting medulloblastoma: small-molecule inhibitors of the Sonic Hedgehog pathway as potential cancer therapeutics. Cancer Res 65:4975-4978.
16. Sanchez P, Clement V, and Ruiz i Altaba A (2005) Therapeutic targeting of the Hedgehog-GLI pathway in prostate cancer. Cancer Res 65:2990-2992.
17. Sarker D and Workman P (2007) Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 96:213-268.
18. Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, and Boulay A, et al. (2008) Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 26:1596-1602.
19. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernández-del Castillo C, and Yajnik V, et al. (2003) Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425:851-856.
20. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, and Baylin SB (2003) Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422:313-317.
21. Wong H, Alicke B, West KA, Pacheco P, La H, Januario T, Yauch RL, de Sauvage FJ, and Gould SE (2011) Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Clin Cancer Res 17: 4682-4692.
22. Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ, and Koudriakova T (2008) Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 36:1267-1274.
23. Zandvliet AS, Schellens JH, Beijnen JH, and Huitema AD (2008) Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. Clin Pharmacokinet 47:487-513.